MoonLake BLA filing advances sonelokimab toward FDA review, but adds no surprise

MoonLake is a single-asset clinical-stage biotech trying to move sonelokimab from late-stage development into its first commercial indication, with hidradenitis suppurativa as the lead regulatory opportunity. Its Phase 3 VELA program had already produced supportive longer-term results, including roughly 67% of treated patients achieving HiSCR75 at Week 52.

The filing clears the main submission milestone. MoonLake submitted a Biologics License Application to the FDA for sonelokimab in moderate-to-severe hidradenitis suppurativa, including adults and patients 12 and older. 〔0〕 This moves the program from clinical development into formal regulatory review, but it does not yet mean the FDA has accepted the application or judged it approvable.

The news is largely execution, not a new surprise. MoonLake had previously described a 2026 BLA submission as its plan, and later reported alignment with the FDA on submission plans and label strategy. The filing therefore confirms that the company met the expected timetable rather than materially changing the underlying story.

The next value-bearing checkpoint is procedural FDA acceptance. The company expects notification on whether the BLA is accepted within approximately 60 days and the planned review timeline within approximately 74 days. 〔1〕 Acceptance would establish that the FDA considers the application sufficiently complete for review; this filing itself provides no new efficacy, safety, labeling, or approval information.

Bottom line: This advances MoonLake’s lead asset exactly as planned, but mostly removes a scheduled execution risk rather than creating a fresh catalyst. The story now shifts from whether MoonLake can file to whether the FDA accepts the application and how it conducts the review.